02121nas a2200301 4500000000100000008004100001260001300042653002000055653003000075653001100105653001800116653003900134653002600173653001200199653002000211100001600231700001300247700001100260700001600271700002000287700001300307700001300320245013400333300001100467490000800478520131900486022001401805 1991 d c1991 Feb10aCells, Cultured10aCytotoxicity, Immunologic10aHumans10aInterleukin-210aKiller Cells, Lymphokine-Activated10aKiller Cells, Natural10aleprosy10aLeukocyte Count1 aHancock G E1 aMolloy A1 aAb B K1 aKiessling R1 aBecx-Bleumink M1 aCohn Z A1 aKaplan G00aIn vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. a277-840 v1323 a

We have examined the effect of the intradermal administration of IL-2 on the generation of natural killer (NK) cell and lymphokine-activated killer (LAK) cell activity. Peripheral blood mononuclear cells (PBMC) obtained from borderline lepromatous (BL) and lepromatous leprosy (LL) patients and normal volunteers prior to and after IL-2 injection were stimulated in vitro with IL-2 and their cytolytic activities compared against 51Cr labeled target K562 cells, Daudi cells, and monocytes. Before IL-2 administration, PBMC obtained from BL/LL patients and normal volunteers possessed similar levels of NK cell activity indicating that the NK cell activity of the BL/LL patients was intact. LAK cell activity was induced with IL-2 in vitro in both BL/LL patients and in normal volunteers. The level of LAK cell activity in BL/LL patients was, however, suboptimal. A single intradermal dose of 25 micrograms IL-2 had no effect on the phenotype of circulating mononuclear cells in either patients or normal volunteers. However, 6-12 days after IL-2 injection and subsequent restimulation of the PBMC with IL-2 in vitro, cytolytic activity of LAK cells obtained from the BL/LL patients was enhanced while cells from normal volunteers expressed the same high levels of activity as observed before IL-2 injection.

 a0008-8749